Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Innovative Platform | Bicycle Therapeutics' proprietary technology drives potential in oncology, with lead asset zelenectide showing promise in metastatic urothelial cancer treatment |
Clinical Milestones | Explore zelenectide's impressive 45% objective response rate and favorable safety profile in recent trials, positioning it as a potential market disrupto |
Financial Strength | With a robust cash position extending into 2027, Bicycle is well-equipped to fund ongoing clinical programs and capitalize on market opportunities |
Analyst Outlook | Price targets range from $26 to $40, reflecting optimism about Bicycle's pipeline and technology platforms, with an average target of $33.50 |
Metrics to compare | BCYC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBCYCPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.7x | −2.9x | −0.5x | |
PEG Ratio | −0.09 | −0.07 | 0.00 | |
Price/Book | 0.7x | 3.5x | 2.6x | |
Price / LTM Sales | 21.2x | 7.6x | 3.3x | |
Upside (Analyst Target) | 221.7% | 319.3% | 43.4% | |
Fair Value Upside | Unlock | 9.5% | 7.1% | Unlock |